Advanced search
Publication Cover
Hematology Volume 24, 2019 - Issue 1
Submit an article Journal homepage
1,713
Views
3
CrossRef citations to date
0
Altmetric
Articles

International sentinel site surveillance of patients with transfusional hemosiderosis treated with deferasirox in actual practice setting

Amal El-BeshlawyCairo University, Cairo, EgyptCorrespondence[email protected]
View further author information
,
Baba InusaEvelina Children’s Hospital, Guy’s and St Thomas’ Hospital NHS Trust, London, UKView further author information
,
David Beneitez PastorHematology Department, Hospital Universitari Vall d’Hebron, Barcelona, SpainORCID Iconhttps://orcid.org/0000-0002-6541-6600View further author information
ORCID Icon,
Blanca XicoyICO-Badalona-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Barcelona, SpainView further author information
,
Maria Soledada Duran NietoDepartamento de Hematologíca, Hospital Materno Infantil de Jaen, Jaén, SpainView further author information
,
Andreas BruederleNovartis Pharma AG, Basel, SwitzerlandView further author information
,
Amin AzmonNovartis Pharma AG, Basel, SwitzerlandView further author information
,
Geralyn GilottiNovartis Pharmaceuticals Corporation, East Hanover, NJ, USAView further author information
&
Mohsen ElalfyAin Shams University, Cairo, EgyptView further author information
 show all
Pages 238-246 | Published online: 17 Dec 2018

References

  • Karami H, Kosaryan M, Amree AH, et al. Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusion-dependent β-thalassemia major. Clin Pract. 2017;7:912. doi: 10.4081/cp.2017.912
  • Cerchione C, Cerciello G, Avilia S, et al. Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease. Blood Transfus. 2016;24:1–4.
  • Cappellini MD. Exjade(R) (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion. Ther Clin Risk Manag. 2007;3:291–299. doi: 10.2147/tcrm.2007.3.2.291
  • Osborne RH, De Abreu Lourenço R, Dalton A, et al. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. Value Health. 2007;10:451–456. doi: 10.1111/j.1524-4733.2007.00200.x
  • Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007;47:1919–1929. doi: 10.1111/j.1537-2995.2007.01416.x
  • Taher AT, Origa R, Perrotta S, et al. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: results of the randomized, phase II ECLIPSE study. Am J Hematol. 2017;92:420–428. doi: 10.1002/ajh.24668
  • Novartis Pharmaceuticals Corporation. EXJADE® (deferasirox) US prescribing information; [cited 2017 Mar 21]. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/exjade.pdf
  • Novartis Pharmaceuticals UK Ltd. Summary of product characteristics – EXJADE 125 mg, 250 mg, 500 mg dispersible tablets; [cited 2017 Mar 21]. Available from: http://www.medicines.org.uk/emc/medicine/18805/SPC/
  • Piga A, Galanello R, Forni GL, et al. Alberti, randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91:873–880.
  • Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107:3455–3462. doi: 10.1182/blood-2005-08-3430
  • Vichinsky E, Onyekwere O, Porter J, et al. Deferasirox in sickle cell investigators. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136:501–508. doi: 10.1111/j.1365-2141.2006.06455.x
  • Sumboonnanonda A, Malasit P, Tanphaichitr VS, et al. Renal tubular function in β-thalassemia. Pediatr Nephrol. 1998;12:280–283. doi: 10.1007/s004670050453
  • Aldudak B, Karabay Bayazit A, Noyan A, et al. Renal function in pediatric patients with β-thalassemia major. Pediatr Nephrol. 2000;15:109–112. doi: 10.1007/s004670000434
  • Origa R, Piga A, Tartaglione I, et al. Similar trends in renal function as measured by serum creatinine during long-term iron chelation treatment with or without deferasirox in patients with transfusional hemosiderosis. EHA (Abs: P288); [cited 2017 Sep 14]. Available from: https://learningcenter.ehaweb.org/eha/2017/22nd/181575/raffaella.origa.similar.trends.in.renal.function.as.measured.by.serum.html
  • Vichinsky E, Bernaudin F, Forni G, et al. Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron overloaded patients with sickle cell disease. Br J Haematol. 2011;154:387–397. doi: 10.1111/j.1365-2141.2011.08720.x
  • Piga A, Fracchia S, Lai ME, et al. Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent β thalassaemia. Br J Haematol. 2015;168:882–890. doi: 10.1111/bjh.13217
  • Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during five years’ follow-up. Blood. 2011;118:884–893. doi: 10.1182/blood-2010-11-316646
  • Jensen PD, Jensen FT, Christensen T, et al. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood. 2003;101:91–96. doi: 10.1182/blood-2002-06-1704
  • Vichinsky E, El-Beshlawy A, Al Zoebie A, et al. Long-term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: results from a 5-year observational study (ENTRUST). Pediatr Blood Cancer. 2017;64:e26507. doi:10.1002/pbc.26507. [Epub ahead of print].

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.